Eli Lilly weight loss drug beats Ozempic in head-to-head study

Pallade Veneta - Eli Lilly weight loss drug beats Ozempic in head-to-head study

HEALTH 08.07.2024

Eli Lilly weight loss drug beats Ozempic in head-to-head study / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

Change text size:

Researchers analyzed the electronic health records of more than 18,000 US patients between May 2022 and September 2023 to compare outcomes among those receiving the two medicines, and published the results in JAMA Internal Medicine.

The average age of the patients was 52, more than 70 percent were female, and the average baseline weight was 110 kilograms (242 lbs). Fifty-two percent had type 2 diabetes.

Most patients achieved five percent or greater weight loss after a year, but those on Mounjaro were more likely to lose weight and achieve weight loss.

Overall, nearly 82 percent of the Mounjaro group saw five percent or greater weight loss compared to 67 percent of the Ozempic group.

The results were 62 percent versus 37 percent for 10 percent or greater weight loss, and 42 percent versus 18 percent for 15 percent or greater weight loss, all in favor of Mounjaro.

At 12 months, the average patient on Mounjaro lost seven percent more weight than the average for Ozempic.

No significant differences were noted in the rates of adverse events between the two groups, though discontinuation of the drug was common among both sets of patients.

Ozempic was approved in the United States in 2017, while Mounjaro received approval in 2022.

A global health scourge, obesity is a risk factor for cardiovascular disease, diabetes, certain cancers and complications from diseases such as Covid-19.

Difficult to treat, it is costly for healthcare systems. While its causes can be lifestyle-related, it can also be influenced by genetics.

I.Saccomanno--PV

Seacliff Healthcare Seeks Specialist GP in Thirroul

Seacliff Healthcare, located in the Illawarra region of New South Wales, is seeking a Specialist General Practitioner to join its team. The practice, situated near Thirroul village station, currently supports five GPs and has capacity for additional medical staff with onsite pathology and allied health services.

India proposes more import entry points for drugs and medical devices

New Delhi The Union Health Ministry has proposed expanding the network of authorised import gateways for drugs, medical devices and cosmetics by adding several inland container depots, a special economic zone and an international airport to facilitate faster clearance and improve supply chain efficiency. The proposed amendment to Rule 43A of the Drugs Rules, 1945, seeks to include additional entry points in Haryana, Uttar Pradesh, Gujarat, Telangana and Karnataka, as reported by a gazette notification issued by the

Why Pregnancy Cost Estimates Fail: A Family’s $9,000 Surprise

Grace Griffin thought she had calculated her pregnancy expenses accurately until bills exceeded $9,000—more than triple her insurer’s estimate. Her experience highlights a systemic failure in healthcare transparency, as federal rules designed to provide accurate cost predictions remain unimplemented. With maternity billing codes set to change next year, experts urge parents to master insurance details and verify every bill.

Kuwait inspectors destroy 115 kilograms of unverified meat in Farwaniya

KUWAIT: The Public Authority for Food and Nutrition (PAFN) issued nine violation reports and destroyed 115 kilograms of meat of unknown origin during an inspection tour of food establishments in Farwaniya Governorate, the authority announced on Monday. The tour was carried out by the authority’s Farwaniya food inspection department.